GlassScriptPhysician profile
Kara J Hoisington
NPI 1588877419
$178,205.28
in general payments reported to CMS, 2019-2025
40 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $38K · 2021: $35K · 2022: $21K · 2023: $2,771 · 2024: $251 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,994 · Food and Beverage: $1,421 · Education: $21.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,993.75 |
| Food and Beverage | $1,420.97 |
| Education | $21.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $73,560.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $35,500.16 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $29,168.82 | 2019-2022 | |
| Lilly USA, LLC | $17,175.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $14,833.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,600.52 | 2019-2020 | |
| Insulet Corporation | $262.80 | 2020-2022 | |
| Grt US Holding, INC. | $193.62 | 2021-2022 | |
| Valeritas, INC. | $172.07 | 2019 | |
| Medtronic Minimed, INC. | $171.58 | 2019 | |
| Averitas Pharma INC. | $155.62 | 2023-2024 | Qutenza |
| Merck Sharp & Dohme LLC | $145.57 | 2019 | |
| Ascendis Pharma Endocrinology INC | $140.19 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $132.14 | 2022-2024 | |
| Dexcom, INC. | $123.65 | 2019-2023 | Dexcom G6 Transmitter |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Hoisington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.